Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 Bispecific CAR-T in R/R B-cell Lymphoma or ALL
NCT06081478Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AUTO3 in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Tongren Hospital. Primary endpoint: Objective Response Rate at 3 months. Started Jan 2022; status: recruiting.
02
Drugs
AUTO3
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06081478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081478.